JP2017536363A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536363A5
JP2017536363A5 JP2017526853A JP2017526853A JP2017536363A5 JP 2017536363 A5 JP2017536363 A5 JP 2017536363A5 JP 2017526853 A JP2017526853 A JP 2017526853A JP 2017526853 A JP2017526853 A JP 2017526853A JP 2017536363 A5 JP2017536363 A5 JP 2017536363A5
Authority
JP
Japan
Prior art keywords
composition
disease
drug
pharmaceutical combination
fibrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536363A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060878 external-priority patent/WO2016081365A1/en
Publication of JP2017536363A publication Critical patent/JP2017536363A/ja
Publication of JP2017536363A5 publication Critical patent/JP2017536363A5/ja
Pending legal-status Critical Current

Links

JP2017526853A 2014-11-19 2015-11-16 リソソーム蓄積症治療のための組成物及び方法 Pending JP2017536363A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081696P 2014-11-19 2014-11-19
US62/081,696 2014-11-19
PCT/US2015/060878 WO2016081365A1 (en) 2014-11-19 2015-11-16 Compositions and methods for treating lysosomal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019232644A Division JP2020100621A (ja) 2014-11-19 2019-12-24 リソソーム蓄積症治療のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2017536363A JP2017536363A (ja) 2017-12-07
JP2017536363A5 true JP2017536363A5 (https=) 2018-10-18

Family

ID=56014423

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017526853A Pending JP2017536363A (ja) 2014-11-19 2015-11-16 リソソーム蓄積症治療のための組成物及び方法
JP2019232644A Pending JP2020100621A (ja) 2014-11-19 2019-12-24 リソソーム蓄積症治療のための組成物及び方法
JP2021063971A Active JP7752958B2 (ja) 2014-11-19 2021-04-05 リソソーム蓄積症治療のための組成物及び方法
JP2021153206A Withdrawn JP2022003060A (ja) 2014-11-19 2021-09-21 リソソーム蓄積症治療のための組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019232644A Pending JP2020100621A (ja) 2014-11-19 2019-12-24 リソソーム蓄積症治療のための組成物及び方法
JP2021063971A Active JP7752958B2 (ja) 2014-11-19 2021-04-05 リソソーム蓄積症治療のための組成物及び方法
JP2021153206A Withdrawn JP2022003060A (ja) 2014-11-19 2021-09-21 リソソーム蓄積症治療のための組成物及び方法

Country Status (9)

Country Link
US (3) US20170354666A1 (https=)
EP (2) EP4026545A1 (https=)
JP (4) JP2017536363A (https=)
KR (1) KR20170083146A (https=)
CN (1) CN107205976A (https=)
AU (1) AU2015350223B2 (https=)
CA (2) CA3176253A1 (https=)
ES (1) ES2914085T3 (https=)
WO (1) WO2016081365A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509030TA (en) 2013-05-07 2015-11-27 Bio Blast Pharma Ltd Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
WO2016081365A1 (en) * 2014-11-19 2016-05-26 Rush University Medical Center Compositions and methods for treating lysosomal disorders
RU2765625C2 (ru) * 2016-06-13 2022-02-01 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
ES2936094T3 (es) * 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
BR112019010210A2 (pt) * 2016-12-29 2019-09-03 Rush University Medical Center melhora na atividade locomotora e aumento da longevidade de indivíduos com lipofuscinose ceroide neuronal infantil tardia por gemfibrozil
US10899844B2 (en) * 2017-02-08 2021-01-26 Novartis Ag FGF21 mimetic antibodies and uses thereof
JP2021511799A (ja) * 2018-01-30 2021-05-13 ラッシュ ユニヴァーシティ メディカル センター 組織および細胞の多重分析のための連続染色
JP7366408B2 (ja) * 2018-02-06 2023-10-23 国立大学法人京都大学 ライソゾーム病の予防及び治療剤
EP3796939A4 (en) * 2018-05-22 2022-03-23 Duke University COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES WITH RIFAXIMIN
US12397004B2 (en) 2018-11-05 2025-08-26 Rush University Medical Center Nasal delivery of low-dose aspirin for the treatment of neurodegenerative and lysosomal storage diseases
AU2020204717B2 (en) 2019-01-03 2025-01-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for increasing transcription factor EB polypeptide levels
US12478598B2 (en) 2019-02-25 2025-11-25 Rush University Medical Center Compositions including cinnamic acid and methods of use thereof
KR20210143848A (ko) * 2019-03-22 2021-11-29 러쉬 유니버시티 메디컬 센터 리소좀 축적 장애를 위한 비강 유전자 전달 및 경구 신남산, 올레아미드 또는 젬피브로질의 병용
EP4028025A4 (en) * 2019-09-09 2023-07-19 University of Pittsburgh - of the Commonwealth System of Higher Education METHODS OF RESTORING LYSOSOMAL FUNCTION OF RETINAL PIGMENT EPITHELIAL CELLS BY TFEB ACTIVATION
CA3150309A1 (en) * 2019-10-01 2021-04-08 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof
CN116723870A (zh) * 2021-01-20 2023-09-08 拉什大学医学中心 球形细胞脑白质营养不良症或克拉伯病的改良治疗
JP2025503457A (ja) * 2021-12-16 2025-02-04 ザ ユナイテッド ステイツ ガバメント アズ リプレゼンティド バイ ザ デパートメント オブ ヴェテランズ アフェアーズ 神経系損傷及び障害の治療のための安息香酸塩
US20250144101A1 (en) * 2022-01-20 2025-05-08 The Johns Hopkins University Lysosomal dysfunction in neurological and psychiatric disorders
US12042476B2 (en) * 2022-02-04 2024-07-23 Mcmaster University Methods for the treatment of lysosomal storage diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311356C (en) 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US20010028895A1 (en) 2000-02-04 2001-10-11 Bisgaier Charles L. Methods of treating alzheimer's disease
PL1732605T3 (pl) * 2004-03-29 2019-09-30 Wyeth Llc Multiwitaminowe i mineralne suplementy odżywcze
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
ES2246737B1 (es) * 2005-06-09 2006-12-01 Jose Juan Rodriguez Jerez "composicion farmaceutica que comprende lisina y usos correspondientes".
JP2009084155A (ja) * 2006-01-16 2009-04-23 Kanazawa Univ レビー小体病治療薬及びレビー小体病予防薬
US20070225360A1 (en) 2006-03-22 2007-09-27 L'oreal Anti-aging composition containing phloretin
GB0718824D0 (en) * 2007-09-26 2007-11-07 Univ Ramot Methods of treating lysosomal storage disorders
US20120114670A1 (en) * 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US9388413B2 (en) * 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
US9388414B2 (en) * 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
JP2010106001A (ja) 2008-10-31 2010-05-13 Theravalues Corp Ｐｐａｒ活性化剤
EP2218458A1 (en) * 2009-02-13 2010-08-18 Fondazione Telethon Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
WO2011049737A1 (en) * 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
WO2012177997A1 (en) * 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
PL399467A1 (pl) * 2012-06-08 2013-12-09 3G Therapeutics Inc. Zastosowanie genisteiny do obnizania poziomu zwiazków organicznych spichrzanych w komórkach w leczeniu i/lub zapobieganiu lizosomalnych chorób spichrzeniowych (LChS)
WO2014089449A1 (en) * 2012-12-07 2014-06-12 Rush University Nedical Center Composition and method for treating neuronal ceroid lipofuscinosis
WO2016081365A1 (en) * 2014-11-19 2016-05-26 Rush University Medical Center Compositions and methods for treating lysosomal disorders

Similar Documents

Publication Publication Date Title
JP2017536363A5 (https=)
Zhang et al. Advances in the pathogenesis of steroid-associated osteonecrosis of the femoral head
Pena-Altamira et al. Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation
Lazo-Gómez et al. Histone deacetylases and their role in motor neuron degeneration
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
NZ743714A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2015503593A5 (https=)
Dubey et al. Recent studies on cellular and molecular mechanisms in Alzheimer’s disease: focus on epigenetic factors and histone deacetylase
WO2012030160A3 (en) Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2007009539A3 (en) Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases
PH12012502447A1 (en) Tetrahydrocarboline derivative
PH12014500371A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2016518338A5 (https=)
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
Oliveira et al. HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015)
HRP20210361T1 (hr) Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
BR112014015578A8 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
WO2011090317A3 (en) Imidazopyrazinone derivatives with apoptosis inducing activity on cells
Khan et al. Epigenetic Regulation Mediating Immunopathology in Parkinson’s Disease
Merchant et al. Animal models of Parkinson's Disease to aid drug discovery and development
Hur Recent Guidelines on the Management of Blood Cholesterol: 2013 ACC/AHA Guidelines and 2014 NICE Draft Guidelines
Maes et al. The DNA methyltransferase inhibitor decitabine induces DNA damage, cell cycle arrest and apoptosis in multiple myeloma